Truqap can be a kinase inhibitor that works by blocking pathways that support the most cancers cells survive and grow, so minimizes most cancers expansion. Truqap is from a class of medicines called an AKT inhibitor. Truqap obtained FDA acceptance on November 17, 2023, just after favourable results within the https://6--hydroxy-paclitaxel47913.spintheblog.com/35158744/not-known-factual-statements-about-trastuzumab-deruxtecan